Drugs / RBS2418
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05270213 | Jul 2022 → Apr 2027 expected | cancer of unknown primary site | Riboscience, LLC. | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05683470 | — | — | Riboscience, LLC. | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07175441 Comparator | Apr 2026 → Apr 2027 expected | hepatocellular carcinoma | Riboscience, LLC. | Recruiting | No outcome recorded |
| Phase 2 | NCT06824064 Comparator | Jan 2025 → Dec 2027 expected | colorectal cancer, metastatic malignant neoplasm in the colon | Riboscience, LLC. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBS2418 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05270213 ↗ |
| Action | Inhibit | “RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1).” NCT05270213 ↗ |
| Modality | Small molecule | “RBS2418 is a potent and selective small molecule inhibitor” NCT05270213 ↗ |
| Route | Oral | “RBS2418 will be administered orally” NCT05683470 ↗ |
| Target | ENPP1 | “inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1)” NCT05270213 ↗ |